Hepatocellular carcinoma
Conditions
Interventions
hospitalization therapy administration via the implanted port of Cisplatin/lipiodol suspension(50mg/body,ia,day1,8) and 5-FU(1250mg/body/day, cia day1-5,8-12) into the hepatic artery every two weeks.
Sponsors
Division of Gastroenterology,Kurume University School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Histologically or clinically confirmed hepatocellular carcinoma. 2.No indication for transplantation or surgical resection. 3.Portal vein tumor thrombosis(main trunk or first branch) or multinodular tumor and maximum tumor size is >=50mm. 4.Ages 30 to 80 years old. 5.EOCG performance status is 0 or 1. 6.Life expectancy is more than 3 months. 7.Sufficient function of main organ(bone marrow, kidney,heart)and conditions filled the following criteria. WBC>=2,000/mm3 Hb>=8.5g/dL Plt>=50,000/mm3 Child-Pugh score<9 T-bil=<2.0mg/dL Without uncontrolled ascites and hepatic encephalopathy. S-Cr=<1.5mg/dL or CCr>=50mL/min Ejection fraction>=45% PaO2>=60mmHg 8.Written informed consent was obtained
Exclusion criteria
Exclusion criteria: 1.previous chemotherapy or TAE 2.Previous operation or RFA or PEIT within one year 3.Extrahepatic metastasis or nodes metastasis 4.Concurrent infections(without hepatitis virus) 5.Active double cancers 6.Medical history of severe hypersensitivity. 7.Pregnant,lacting women or women with suspected pregnancy. 8.Inappropriate patients for this study judged by physicians.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progrssion free survival | — |
Secondary
| Measure | Time frame |
|---|---|
| Overall survival response evaluation complicasion | — |
Countries
Japan
Contacts
Public ContactHiroaki Nagamatsu
Yame General Hospital Department of Gastroenterology and Hepatology
Outcome results
None listed